Literature DB >> 27755151

Epstein-Barr virus associated lymphomas in people with HIV.

Antonino Carbone1, Chiara C Volpi, Ambra V Gualeni, Annunziata Gloghini.   

Abstract

PURPOSE OF REVIEW: The present review summarizes the association of the different histotypes of Epstein-Barr virus (EBV)-associated lymphomas with known genetic lesions and/or oncogenic viruses. A more comprehensive understanding of the complex interplay existing between genetic abnormalities of tumor cells and the viral contribution to the development of EBV-associated lymphomas is pivotal for the development of more effective treatments. RECENT
FINDINGS: Recent evidence indicates that HIV may contribute to lymphomagenesis by acting directly on B lymphocytes as a critical microenvironmental factor. The pathogenesis of EBV-associated lymphomas in patients with HIV infection is considered the result of the concerted action of different factors, mainly including impaired immune surveillance, genetic alterations, and concomitant viral infection (EBV and HIV).
SUMMARY: Immunodeficiency states usually increase susceptibility to cancer as a result of reduced immune surveillance and enhanced chances for virus-driven oncogenesis. Lymphoma remains the most frequent neoplastic cause of death among patients infected with HIV. Several of the HIV-associated lymphomas are related to EBV infection. EBV-associated lymphomas in patients infected with HIV are heterogeneous, not only pathologically but also in terms of pathogenetic pathways and cellular derivation.

Entities:  

Mesh:

Year:  2017        PMID: 27755151     DOI: 10.1097/COH.0000000000000333

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  14 in total

Review 1.  Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Authors:  Andres Chang; Danielle Schlafer; Christopher R Flowers; Pamela B Allen
Journal:  Expert Opin Investig Drugs       Date:  2017-12-24       Impact factor: 6.206

2.  CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Authors:  Mohamed Abdel-Mohsen; Leticia Kuri-Cervantes; Judith Grau-Exposito; Adam M Spivak; Racheal A Nell; Costin Tomescu; Surya Kumari Vadrevu; Leila B Giron; Carla Serra-Peinado; Meritxell Genescà; Josep Castellví; Guoxin Wu; Perla M Del Rio Estrada; Mauricio González-Navarro; Kenneth Lynn; Colin T King; Sai Vemula; Kara Cox; Yanmin Wan; Qingsheng Li; Karam Mounzer; Jay Kostman; Ian Frank; Mirko Paiardini; Daria Hazuda; Gustavo Reyes-Terán; Douglas Richman; Bonnie Howell; Pablo Tebas; Javier Martinez-Picado; Vicente Planelles; Maria J Buzon; Michael R Betts; Luis J Montaner
Journal:  Sci Transl Med       Date:  2018-04-18       Impact factor: 17.956

3.  Clinical and scientific challenges in HIV-associated malignancies.

Authors:  Mark N Polizzotto; Ronald T Mitsuyasu
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

4.  HIV co-infection augments EBV-induced tumorigenesis in vivo.

Authors:  Christopher B Whitehurst; Monica Rizk; Adonay Teklezghi; Rae Ann Spagnuolo; Joseph S Pagano; Angela Wahl
Journal:  Front Virol       Date:  2022-03-11

Review 5.  Role of Natural Killer Cells in HIV-Associated Malignancies.

Authors:  Fabio E Leal; Thomas A Premeaux; Mohamed Abdel-Mohsen; Lishomwa C Ndhlovu
Journal:  Front Immunol       Date:  2017-03-21       Impact factor: 7.561

6.  Epstein Barr Virus-Associated Hodgkin Lymphoma.

Authors:  Antonino Carbone; Annunziata Gloghini
Journal:  Cancers (Basel)       Date:  2018-05-25       Impact factor: 6.639

Review 7.  Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus.

Authors:  Abhik Saha; Erle S Robertson
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

8.  Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.

Authors:  Laura E Martínez; Shelly Lensing; Di Chang; Larry I Magpantay; Ronald Mitsuyasu; Richard F Ambinder; Joseph A Sparano; Otoniel Martínez-Maza; Marta Epeldegui
Journal:  Clin Cancer Res       Date:  2021-06-15       Impact factor: 12.531

Review 9.  Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

Authors:  Mohamed Abdel-Mohsen; Douglas Richman; Robert F Siliciano; Michel C Nussenzweig; Bonnie J Howell; Javier Martinez-Picado; Nicolas Chomont; Katharine J Bar; Xu G Yu; Mathias Lichterfeld; Jose Alcami; Daria Hazuda; Frederic Bushman; Janet D Siliciano; Michael R Betts; Adam M Spivak; Vicente Planelles; Beatrice H Hahn; Davey M Smith; Ya-Chi Ho; Maria J Buzon; Christian Gaebler; Mirko Paiardini; Qingsheng Li; Jacob D Estes; Thomas J Hope; Jay Kostman; Karam Mounzer; Marina Caskey; Lawrence Fox; Ian Frank; James L Riley; Pablo Tebas; Luis J Montaner
Journal:  Nat Med       Date:  2020-09-07       Impact factor: 87.241

10.  Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells.

Authors:  Jinshun Zhu; Saidu Kamara; Danwei Cen; Wanlin Tang; Meiping Gu; Xingyuan Ci; Jun Chen; Lude Wang; Shanli Zhu; Pengfei Jiang; Shao Chen; Xiangyang Xue; Lifang Zhang
Journal:  Cell Death Dis       Date:  2020-04-01       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.